Australia - inglés - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - testosterone, quantity: 0.0125 g - gel - excipient ingredients: ethanol; isopropyl myristate; purified water; carbomer 980; sodium hydroxide - indicated for use as testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; hypromellose; titanium dioxide; purified talc; macrogol 6000 - entecavir sandoz is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: purified talc; hypromellose; titanium dioxide; lactose monohydrate; crospovidone; magnesium stearate; microcrystalline cellulose; macrogol 6000; iron oxide red; iron oxide yellow - entecavir sandoz is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; crospovidone; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; crospovidone; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - entecavir is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment na?ve and lamividine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - adefovir dipivoxil, quantity: 10 mg - tablet - excipient ingredients: pregelatinised maize starch; magnesium stearate; purified talc; croscarmellose sodium; lactose monohydrate - ? adefovir dipivoxil is indicated for the treatment of chronic hepatitis b in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alt or ast) or histologically active disease. ? for adult patients, this indication is based on histological, virological, biochemical, and serological responses in adult patients with hbeag+ and hbeag-/hbvdna+ chronic hepatitis b with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis b virus with either compensated or decompensated liver function. ? for adolescent patients (12 to <18 years of age), the indication is based on virological and biochemical responses in patients with hbeag+ chronic hepatitis b virus with compensated liver function.

Estados Unidos - inglés - NLM (National Library of Medicine)

dah wei biochemical pharmaceutic international ltd. - levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et) - levomenthol 200 mg in 5 g - external analgesic for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis strains, bruises and sprains.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - mesterolone, quantity: 25 mg - tablet, uncoated - excipient ingredients: propyl hydroxybenzoate; lactose monohydrate; povidone; magnesium stearate; methyl hydroxybenzoate; maize starch - hypogonadism - androgen replacement for male hypogonadism, where there is androgen deficiency confirmed by clinical and biochemical testing (see 'precautions' and 'dosage and administration').

Australia - inglés - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - entecavir, quantity: 1 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; macrogol 400 - baraclude is indicated for the treatment of chronic hepatitis b virus infection infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - entecavir, quantity: 0.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; povidone; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - baraclude is indicated for the treatment of chronic hepatitis b virus infection in adults 16 years or older with evidence of active liver inflammation. this indication is based on histologic, virologic, biochemical and serological responses in nucleoside-treatment naive and lamivudine-resistant adult patients with hbeag-positive or hbeag-negative chronic hbv infection with compensated liver disease.